Assessment of the antimalarial potential of tetraoxane WR 148999

J. L. Vennerstrom, Jr Ager, S. L. Andersen, J. M. Grace, V. Wongpanich, C. K. Angerhofer, J. K. Hu, D. L. Wesche

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The antimalarial peroxide, dispiro-1,2,4,5-tetraoxane WR 148999, was synergistic with chloroquine, quinine, mefloquine, and artemisinin against both D6 and W2 clones of Plasmodium falciparum. In consideration of the contrasting antagonism between artemisinin and chloroquine, these drug combination data imply that WR 148999 and artemisinin may not share a common mechanism of action. For Plasmodium berghei-infected mice given oral, subcutaneous, and intraperitoneal doses of WR 148999 ranging from 2 to 1024 mg/kg in the Thompson test, median survival times were 8.8, 11.8, and 27.5 days, respectively, compared to 8 days for control animals. Using subcutaneous administration, WR 148999 had a considerably longer duration of action than did artemisinin against P. berghei. WR 148999 did not significantly inhibit cytochrome P450 isozymes CYP 2C9, 2C19, 2D6, 2E1, or 3A4 (IC50 >500 μM) but did inhibit CYP 1A2 with an IC50 value of 36 μM, suggesting that WR 148999 may be metabolized by the latter CYP isozyme. These results combined with previous observations that formulation strategies and incorporation of polar functional groups in a series of WR 148999 analogs both failed to enhance tetraoxane oral antimalarial activity suggest that oral bioavailability of tetraoxane WR 148999 is more likely a function of extensive first-pass metabolism rather than solubility-limited dissolution.

Original languageEnglish (US)
Pages (from-to)573-578
Number of pages6
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume62
Issue number5
DOIs
StatePublished - Jan 1 2000

Fingerprint

Tetraoxanes
Antimalarials
Plasmodium berghei
Chloroquine
Isoenzymes
Inhibitory Concentration 50
Mefloquine
Cytochrome P-450 CYP1A2
Quinine
dispiro-1,2,4,5-tetroxane
Peroxides
Drug Combinations
Plasmodium falciparum
Solubility
Cytochrome P-450 Enzyme System
Biological Availability
Clone Cells

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases
  • Virology

Cite this

Vennerstrom, J. L., Ager, J., Andersen, S. L., Grace, J. M., Wongpanich, V., Angerhofer, C. K., ... Wesche, D. L. (2000). Assessment of the antimalarial potential of tetraoxane WR 148999. American Journal of Tropical Medicine and Hygiene, 62(5), 573-578. https://doi.org/10.4269/ajtmh.2000.62.573

Assessment of the antimalarial potential of tetraoxane WR 148999. / Vennerstrom, J. L.; Ager, Jr; Andersen, S. L.; Grace, J. M.; Wongpanich, V.; Angerhofer, C. K.; Hu, J. K.; Wesche, D. L.

In: American Journal of Tropical Medicine and Hygiene, Vol. 62, No. 5, 01.01.2000, p. 573-578.

Research output: Contribution to journalArticle

Vennerstrom, JL, Ager, J, Andersen, SL, Grace, JM, Wongpanich, V, Angerhofer, CK, Hu, JK & Wesche, DL 2000, 'Assessment of the antimalarial potential of tetraoxane WR 148999', American Journal of Tropical Medicine and Hygiene, vol. 62, no. 5, pp. 573-578. https://doi.org/10.4269/ajtmh.2000.62.573
Vennerstrom, J. L. ; Ager, Jr ; Andersen, S. L. ; Grace, J. M. ; Wongpanich, V. ; Angerhofer, C. K. ; Hu, J. K. ; Wesche, D. L. / Assessment of the antimalarial potential of tetraoxane WR 148999. In: American Journal of Tropical Medicine and Hygiene. 2000 ; Vol. 62, No. 5. pp. 573-578.
@article{4f3aa99cd8cf49a3be0d065c962e84c5,
title = "Assessment of the antimalarial potential of tetraoxane WR 148999",
abstract = "The antimalarial peroxide, dispiro-1,2,4,5-tetraoxane WR 148999, was synergistic with chloroquine, quinine, mefloquine, and artemisinin against both D6 and W2 clones of Plasmodium falciparum. In consideration of the contrasting antagonism between artemisinin and chloroquine, these drug combination data imply that WR 148999 and artemisinin may not share a common mechanism of action. For Plasmodium berghei-infected mice given oral, subcutaneous, and intraperitoneal doses of WR 148999 ranging from 2 to 1024 mg/kg in the Thompson test, median survival times were 8.8, 11.8, and 27.5 days, respectively, compared to 8 days for control animals. Using subcutaneous administration, WR 148999 had a considerably longer duration of action than did artemisinin against P. berghei. WR 148999 did not significantly inhibit cytochrome P450 isozymes CYP 2C9, 2C19, 2D6, 2E1, or 3A4 (IC50 >500 μM) but did inhibit CYP 1A2 with an IC50 value of 36 μM, suggesting that WR 148999 may be metabolized by the latter CYP isozyme. These results combined with previous observations that formulation strategies and incorporation of polar functional groups in a series of WR 148999 analogs both failed to enhance tetraoxane oral antimalarial activity suggest that oral bioavailability of tetraoxane WR 148999 is more likely a function of extensive first-pass metabolism rather than solubility-limited dissolution.",
author = "Vennerstrom, {J. L.} and Jr Ager and Andersen, {S. L.} and Grace, {J. M.} and V. Wongpanich and Angerhofer, {C. K.} and Hu, {J. K.} and Wesche, {D. L.}",
year = "2000",
month = "1",
day = "1",
doi = "10.4269/ajtmh.2000.62.573",
language = "English (US)",
volume = "62",
pages = "573--578",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "5",

}

TY - JOUR

T1 - Assessment of the antimalarial potential of tetraoxane WR 148999

AU - Vennerstrom, J. L.

AU - Ager, Jr

AU - Andersen, S. L.

AU - Grace, J. M.

AU - Wongpanich, V.

AU - Angerhofer, C. K.

AU - Hu, J. K.

AU - Wesche, D. L.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The antimalarial peroxide, dispiro-1,2,4,5-tetraoxane WR 148999, was synergistic with chloroquine, quinine, mefloquine, and artemisinin against both D6 and W2 clones of Plasmodium falciparum. In consideration of the contrasting antagonism between artemisinin and chloroquine, these drug combination data imply that WR 148999 and artemisinin may not share a common mechanism of action. For Plasmodium berghei-infected mice given oral, subcutaneous, and intraperitoneal doses of WR 148999 ranging from 2 to 1024 mg/kg in the Thompson test, median survival times were 8.8, 11.8, and 27.5 days, respectively, compared to 8 days for control animals. Using subcutaneous administration, WR 148999 had a considerably longer duration of action than did artemisinin against P. berghei. WR 148999 did not significantly inhibit cytochrome P450 isozymes CYP 2C9, 2C19, 2D6, 2E1, or 3A4 (IC50 >500 μM) but did inhibit CYP 1A2 with an IC50 value of 36 μM, suggesting that WR 148999 may be metabolized by the latter CYP isozyme. These results combined with previous observations that formulation strategies and incorporation of polar functional groups in a series of WR 148999 analogs both failed to enhance tetraoxane oral antimalarial activity suggest that oral bioavailability of tetraoxane WR 148999 is more likely a function of extensive first-pass metabolism rather than solubility-limited dissolution.

AB - The antimalarial peroxide, dispiro-1,2,4,5-tetraoxane WR 148999, was synergistic with chloroquine, quinine, mefloquine, and artemisinin against both D6 and W2 clones of Plasmodium falciparum. In consideration of the contrasting antagonism between artemisinin and chloroquine, these drug combination data imply that WR 148999 and artemisinin may not share a common mechanism of action. For Plasmodium berghei-infected mice given oral, subcutaneous, and intraperitoneal doses of WR 148999 ranging from 2 to 1024 mg/kg in the Thompson test, median survival times were 8.8, 11.8, and 27.5 days, respectively, compared to 8 days for control animals. Using subcutaneous administration, WR 148999 had a considerably longer duration of action than did artemisinin against P. berghei. WR 148999 did not significantly inhibit cytochrome P450 isozymes CYP 2C9, 2C19, 2D6, 2E1, or 3A4 (IC50 >500 μM) but did inhibit CYP 1A2 with an IC50 value of 36 μM, suggesting that WR 148999 may be metabolized by the latter CYP isozyme. These results combined with previous observations that formulation strategies and incorporation of polar functional groups in a series of WR 148999 analogs both failed to enhance tetraoxane oral antimalarial activity suggest that oral bioavailability of tetraoxane WR 148999 is more likely a function of extensive first-pass metabolism rather than solubility-limited dissolution.

UR - http://www.scopus.com/inward/record.url?scp=0034468693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034468693&partnerID=8YFLogxK

U2 - 10.4269/ajtmh.2000.62.573

DO - 10.4269/ajtmh.2000.62.573

M3 - Article

C2 - 11289666

AN - SCOPUS:0034468693

VL - 62

SP - 573

EP - 578

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 5

ER -